[Report on the clinical testing of the delayed-action form of the neuroleptic agent moperone hydrochloride in 20 chronic psychotic patients].

The sustained release form of butyrophenone derivative moperone hydrochloride was tested within the scope of an open clinical study including 20 patients with mostly chronic, schizophrenic psychoses. Five patients were prematurely dropped from the trial for various reasons. Generally speaking, marked improvement was observed for the remaining 15 patients after the five-week test period as compared to previous neuroleptic medication. Three patients exhibited extrapyramidal reactions; no other side effects were observed. Gastric tolerance of the tablets was very good.